R. Jain

发表

GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy

G. Sonpavde, T. Wheeler, M. Ittmann, 2011, Clinical Cancer Research.

Denosumab for treatment of hypercalcemia of malignancy.

G. Tonini, R. Jain, S. Leboulleux, 2014, The Journal of clinical endocrinology and metabolism.

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.

A. Logan, D. DeAngelo, M. Bishop, 2021, Blood.

Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies

R. Kurzrock, A. Naing, D. Hong, 2015, Cell cycle.

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

Michael L. Wang, R. Houot, M. Kersten, 2020, The New England journal of medicine.

A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors

M. Egorin, D. Trump, Candace S. Johnson, 2011, Investigational New Drugs.

Addition of losartan to FOLFORINOX and chemoradiation downregulates pro-invasion and immunosuppression-associated genes in locally advanced pancreatic cancer

Jeffrey, Y. Boucher, M. Mino‐Kenudson, 2022, medRxiv.

Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment

R. Jain, S. Leboulleux, I. Glezerman, 2013, Journal of the National Cancer Institute.

Food and Oral Antineoplastics: More Than Meets the Eye

L. Lesko, R. Jain, S. Brar, 2010, Clinical Cancer Research.

Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia

A. Baruchel, M. Hermiston, B. K. Masouleh, 2022, Haematologica.

A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial.

Yoon-Koo Kang, K. Muro, R. Jain, 2015 .

Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment

Yilong Zhang, R. Jain, Min Zhu, 2015, Biomedicines.

Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.

J Jack Lee, Razelle Kurzrock, Chaan Ng, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib-induced acute hemolysis without hypertension: a case report.

C. Wood, R. Jain, N. Tannir, 2008, Clinical genitourinary cancer.

A Randomized, Placebo‐Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum‐Based Chemotherapy as First‐Line Treatment for Extensive‐Stage Small‐Cell Lung Cancer

K. Nackaerts, R. Ramlau, L. Paz-Ares, 2017, Clinical lung cancer.

Prevalence of hypercalcemia among cancer patients in the United States

A. Liede, R. Jain, L. Schwartzberg, 2016, Cancer medicine.

Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma

A. Belldegrun, A. Pantuck, D. Elashoff, 2019, Cancer Immunology, Immunotherapy.

End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

A. Logan, M. Bishop, J. Pagel, 2019, Journal of Clinical Oncology.

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

Razelle Kurzrock, Maurie Markman, J. Jack Lee, 2010, Clinical Cancer Research.

Imaging in Diabetes Mellitus

R. Jain, 2016 .

RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.

J. Lee, R. Kurzrock, D. Hong, 2013, Journal of the National Cancer Institute.

Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM).

G. Tonini, R. Jain, S. Leboulleux, 2013 .

Unlocking the potential of non-coding RNAs in cancer research and therapy

R. Jain, Kalyani Palasamudram, A. Gaur, 2023, Translational oncology.

Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

M. Sabatino, J. Rossi, M. Bishop, 2017 .

PS962 PHASE 1 RESULTS OF ZUMA-4: KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA

A. Baruchel, M. Hermiston, R. Jain, 2019, HemaSphere.

ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)

M. Kersten, G. Schiller, W. Wierda, 2016 .

Denosumab for treatment of hypercalcemia of malignancy.

G. Tonini, R. Jain, S. Leboulleux, 2014, The Journal of clinical endocrinology and metabolism.

GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy

G. Sonpavde, T. Wheeler, M. Ittmann, 2011, Clinical Cancer Research.

Reply to A. Levy et al.

R. Kurzrock, D. Hong, R. Jain, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imaging in Diabetes Mellitus

R. Jain, 2016 .

Food and Oral Antineoplastics: More Than Meets the Eye

L. Lesko, R. Jain, S. Brar, 2010, Clinical Cancer Research.

KTE-C19, an Anti-CD19 Chimeric Antigen an Anti-CD19 Chimeric Antigen Receptor (CAR) T cell Therapy in Adult Patients (Pts) With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the ZUMA-3 Trial: Preliminary Results of Novel Safety Interventions

R. Houot, M. Kersten, J. Rossi, 2017 .